DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for focal dermal hypoplasia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFocal dermal hypoplasia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for focal dermal hypoplasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Focal dermal hypoplasia, also called Goltz syndrome, is an X-linked dominant disorder of ecto-mesenchymal development. The condition is characterised by widespread dysplasia of mesodermal and ectodermal structures, including undevelopment and maldevelopment of the dermis. Typical skin manifestations are linear streaks of hypoplastic dermis that expose subcutaneous fat. Additional phenotypic features include skeletal, ocular, dental and facial abnormalities, abdominal wall defects, urogenital abnormalities and diaphragmatic hernia. The syndrome must be distinguished from congenital poikiloderma, connective tissue nevi, anhidrotic and hidrotic ectodermal dysplasias, and incontinentia pigmenti. Some cases of localised congenital absence of the skin may represent incomplete forms.
Most affected individuals are females. Although the disorder is normally lethal in male patients, approximately 10% of cases are male, and most of those represent post-zygotic mosaicism. Mildly affected males who can have severely affected daughters represent a small minority of cases. As of 1970, approximately 46 cases were known. The condition is caused by mutations in PORCN, an essential gene on the X chromosome that is subject to X inactivation and encodes an important regulator of WNT protein secretion. Disrupted WNT signalling probably explains the various phenotypic features, while varying levels of X inactivation and somatic mosaicism for mutations may explain the variable severity.
No drug treatment is described in any of these abstracts. The literature is limited to case reports and genetic characterisation. There are no clinical trials, no survival data, no response rates, and no mention of any pharmacological intervention for focal dermal hypoplasia.
What is still missing is any clinical trial design, any funding for drug development, and any patient stratification beyond the genetic diagnosis. The natural history of the condition is poorly quantified, and no outcome measures have been established for potential therapeutic studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Dermatology · 1970 · 171 citations
Focal Dermal Hypoplasia Syndrome
AbstractFocal dermal hypoplasia is characterized by widespread dysplasia of mesodermal and ectodermal structures, including undevelopment and maldevelopment of the dermis. Approximately 46 such cases are now known and we are reporting two additional children. The abnormal findings in previously published cases have been collected and are presented in tabular form. This syndrome must be distinguished from congenital poikiloderma, connective tissue nevi, anhidrotic and hidrotic ectodermal dysplasias, and incontinentia pigmenti. Some cases of localized congenital absence of the skin may represent incomplete forms. Presently available evidence suggests that the focal dermal hypoplasia syndrome is genetically determined.
A Case of Almost Unilateral Focal Dermal Hypoplasia Resulting From a Novel Mutation in the Gene
AbstractFocal dermal hypoplasia (FDH), also known as Goltz syndrome, is an X-linked dominant disorder of ecto-mesenchymal development. In general, FDH presents with characteristic linear streaks of hypoplastic dermis and various abnormalities in some organs (1). Although this disorder is normally lethal in male patients, ap-proximately 10% of cases of FDH are male, and most represent post-zygotic mosaicism (2–4). The molecular basis of FDH involves mutations in the
Harper's Textbook of Pediatric Dermatology · 2011 · 1 citations
Focal Dermal Hypoplasia
AbstractFocal dermal hypoplasia is a rare congenital mesoectodermal disorder, first described in 1962 by Goltz et al., who coined the name ‘focal dermal hypoplasia’ to describe the focal areas of decreased connective tissue in the skin exposing subcutaneous fat. The combination of typical skin manifestations and one or more characteristic skeletal, ocular, dental and facial features supports a clinical diagnosis of focal dermal hypoplasia. Other phenotypic features include abdominal wall defects, urogenital abnormalities and diaphragmatic hernia. Most affected individuals are females; mildly affected males who can have severely affected daughters represent a small minority of cases. Focal dermal hypoplasia is caused by mutations in PORCN, an essential gene on the X chromosome that is subject to X inactivation and encodes an important regulator of WNT protein secretion. Disrupted WNT signalling probably explains the various phenotypic features of focal dermal hypoplasia, while varying levels of X inactivation and somatic mosaicism for mutations may explain the variable severity.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
